Tillett et al. Baseline characteristics and achievement of MDA at week 24 with IL23i guselkumab in bDMARD experienced patients. Pattern of joint (wrist vs shoulder/hand) and skin (scalp vs hand/foot) involvement, as well as male sex, predictive @RheumNow #EULAR2022 POS1051 https://t.co/lHOTgMWgMA

Prof McInnes @IainBMcInnes1 et al. IL23i guselkumab efficacy maintained irrespective of baseline characteristics of patients. I kind of wish in some of these studies that we would see big differences to help us select between agents! @RheumNow #EULAR2022 POS0072 https://t.co/zJWvpwcDkt

Mease et al. Minimal radiographic progression in patients treated with IL-23i guselkumab over 2 years. This trial enriched for high-risk radiographic progression. Clinical response associated with less radiographic progression. @RheumNow #EULAR2022 POS1035 https://t.co/1C21MNVpV8

Dr Gossec et al. Multidomain indices show consistent benefit when applied to IL23i guselkumab COSMOS trial. I like MDA (because its simple and so am I) so showing that. But same benefits seen in DAPSA, PASDAS, mCPDAI, GRACE, PsARC. @RheumNow #EULAR2022 POS1038 https://t.co/EU2VHpEGc3

Mease et al. IL23i guselkumab on axial outcomes in PsA at 2 years in DISCOVER-2. Guselkumab improves BASDAI, mBASDAI, spinal pain, ASDAS to week 100. Still trying to get my head around this seeming to work for PsA spinal disease but not axSpA @RheumNow #EULAR2022 POS1037 https://t.co/LZgXEl6Ohl

Does diet drive IL-23 in IBD and PsA? Perhaps if you have the right baseline risk. The science is evolving quickly Stronger rationale that diet may be really important in some patients #EULAR2022 #IL23 @RheumNow https://t.co/hV54PvfOXV

Zabotti et al. IL23i guselkumab. Machine learning identified clusters of MDA response @RheumNow #EULAR2022 OP0259 https://t.co/67tfuADxLs https://t.co/33Y5m37K3y

• EULAR Abstract Archive

Merola et al. Risankizumab on MDA and DAPSA in KEEPsAKE 1 and 2. Week 24 MDA 25.0/25.6% vs 10.2/11.4%. DAPSA LDA+REM 41.2/36.8% week 24, 59.2/44.6% week 52 @RheumNow #EULAR2022 POS1029 https://t.co/Uz7kA76pMH

Kristensen et al. 52 week results KEEPsAKE 1 RCT risankizumab vs PBO to week 24, then rescue, in csDMARD-IR PsA. ACR20 57% vs 34% (PBO) week 24, week 52 70%/63% ACR20. ACR 50/70 similar differences. PASI even better. @RheumNow #EULAR2022 POS1024 https://t.co/USQsMQ7oxu

Baseline molecular differences noted in PsA patients who are TNFi naive and incomplete responders. Elevated IL-22 expression may suggest increased involvement of IL-23 pathway in TNF-IR pts. @RheumNow #EULAR2022 ABST#POS0074